Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The compensation committee approved non-qualified stock options for one new employee to purchase 25,000 shares of common stock on March 3, 2025. The stock options will vest quarterly over four years, with 1/16 of shares vesting each quarter, contingent on continued employment. This grant was made under Biomea's 2023 Inducement Equity Plan, which was adopted by the board on November 17, 2023, as an inducement for employment.
Biomea Fusion (Nasdaq: BMEA), un'azienda in fase clinica che sviluppa farmaci per il diabete e l'obesità, ha annunciato un'induzione ai sensi della Regola di Quotazione Nasdaq 5635(c)(4). Il comitato per la compensazione ha approvato opzioni su azioni non qualificate per un nuovo dipendente, permettendo l'acquisto di 25.000 azioni ordinarie il 3 marzo 2025. Le opzioni su azioni matureranno trimestralmente nel corso di quattro anni, con 1/16 delle azioni che maturerà ogni trimestre, a condizione di un'occupazione continuativa. Questa concessione è stata effettuata nell'ambito del Piano di Induzione Azionaria 2023 di Biomea, adottato dal consiglio il 17 novembre 2023, come incentivo per l'assunzione.
Biomea Fusion (Nasdaq: BMEA), una empresa en etapa clínica de medicamentos para la diabetes y la obesidad, ha anunciado una concesión de inducción bajo la Regla de Cotización 5635(c)(4) de Nasdaq. El comité de compensación aprobó opciones sobre acciones no calificadas para un nuevo empleado, permitiendo la compra de 25,000 acciones comunes el 3 de marzo de 2025. Las opciones sobre acciones se consolidarán trimestralmente durante cuatro años, con 1/16 de las acciones consolidándose cada trimestre, sujeto a la continuación del empleo. Esta concesión se realizó bajo el Plan de Equidad de Inducción 2023 de Biomea, que fue adoptado por la junta el 17 de noviembre de 2023, como un incentivo para el empleo.
Biomea Fusion (Nasdaq: BMEA), 당뇨병 및 비만 치료제를 개발하는 임상 단계의 회사는 Nasdaq 상장 규정 5635(c)(4)에 따라 유도 보상을 발표했습니다. 보상 위원회는 새로운 직원이 2025년 3월 3일에 25,000주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다. 주식 옵션은 4년에 걸쳐 분기별로 발생하며, 매 분기마다 1/16의 주식이 발생하며, 계속 고용되는 조건입니다. 이 보상은 Biomea의 2023 유도 주식 계획에 따라 이루어졌으며, 이 계획은 2023년 11월 17일 이사회에서 채택되어 고용 유도를 위한 것입니다.
Biomea Fusion (Nasdaq: BMEA), une entreprise en phase clinique spécialisée dans les médicaments contre le diabète et l'obésité, a annoncé une attribution d'incitation conformément à la règle de cotation Nasdaq 5635(c)(4). Le comité de rémunération a approuvé des options d'achat d'actions non qualifiées pour un nouvel employé, lui permettant d'acheter 25 000 actions ordinaires le 3 mars 2025. Les options d'achat d'actions seront acquises trimestriellement pendant quatre ans, avec 1/16 des actions acquises à chaque trimestre, sous réserve d'un emploi continu. Cette attribution a été effectuée dans le cadre du Plan d'Équité d'Induction 2023 de Biomea, qui a été adopté par le conseil d'administration le 17 novembre 2023, en tant qu'incitation à l'emploi.
Biomea Fusion (Nasdaq: BMEA), ein Unternehmen in klinischer Phase für Medikamente gegen Diabetes und Fettleibigkeit, hat eine Induktionszusage gemäß der Nasdaq-Listing-Regel 5635(c)(4) bekannt gegeben. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen für einen neuen Mitarbeiter, die den Kauf von 25.000 Stammaktien am 3. März 2025 ermöglichen. Die Aktienoptionen werden vierteljährlich über vier Jahre fällig, wobei jedes Quartal 1/16 der Aktien fällig wird, abhängig von einer fortgesetzten Beschäftigung. Diese Zusage wurde im Rahmen des Induktionsaktienplans 2023 von Biomea getroffen, der am 17. November 2023 vom Vorstand angenommen wurde, um die Beschäftigung zu fördern.
- None.
- None.
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 3, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company’s common stock. The shares underlying the employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to the employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.
About Biomea Fusion
Biomea is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic disease. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com
FAQ
How many shares were granted in Biomea Fusion's (BMEA) March 2025 inducement grant?
What is the vesting schedule for BMEA's March 2025 inducement stock options?
When was Biomea Fusion's (BMEA) 2023 Inducement Equity Plan adopted?
Under which Nasdaq rule was BMEA's March 2025 inducement grant issued?
